Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying how mobile-based education affects women undergoing surgery for gynecological cancer. The study aims to see if this education can improve symptom control and enhance quality of life after surgery. It is a randomized controlled experimental design conducted by Istanbul University - Cerrahpasa. Women participating will be randomly divided into two groups an experimental group receiving education through a specially developed mobile care support application, and a control group that will have no intervention aside from data collection. The study plans to include about 70 women, with 35 in each group, and will use several questionnaires and forms to collect data. Participants will be assessed two weeks after surgery using quality of life and symptom control measures. Data will be analyzed to compare changes between and within groups. The study involves completing forms like the Functional Assessment of Cancer Therapy-General and usability questionnaires to evaluate the mobile application. All data will be analyzed statistically to determine the impact of the education.
Actively Recruiting
Researchers are evaluating a new combination treatment of Sigvotatug Vedotin plus pembrolizumab compared to pembrolizumab alone in people with non-small cell lung cancer NSCLC that has high levels of PD-L1 protein. This protein can limit the bodys immune response to cancer. The study focuses on participants with advanced NSCLC Stage 3 or 4 who have PD-L1 expression in over 50% of their cancer cells and who are eligible for pembrolizumab treatment. All participants will receive pembrolizumab through an intravenous infusion every six weeks at the study clinic. Half of the participants will also receive Sigvotatug Vedotin as an intravenous infusion every two weeks alongside pembrolizumab. Participants may continue pembrolizumab treatment for up to about two years, while those receiving Sigvotatug Vedotin can continue until their cancer no longer responds to treatment. During the study, participants will visit the clinic regularly for monitoring, including assessments of overall survival and progression-free survival over approximately two years. The research team will evaluate how well participants respond to treatment and monitor side effects. Additional laboratory tests will assess drug levels and immune responses. The total study participation may last up to four years, with ongoing evaluations to measure treatment effects and safety.